Not a Carbon Copy: FDA’s Updated Rules for Biosimilar Development and Manufacturing

On this episode of The Regulatory Mix, the discussion focuses on FDA’s updated 2026 guidance for biosimilar and interchangeable biological products and what it means for development strategy, product design, pediatric requirements, and postapproval manufacturing.

FDA’s latest Q&A reinforces an important principle: a biosimilar does not have to be an exact physical copy of its reference product. Sponsors may use different formulations, container closure systems, or delivery devices, and they may seek approval for fewer indications, presentations, or routes than the reference product. But that flexibility has clear statutory limits. A 351(k) applicant cannot use the abbreviated pathway to introduce a different strength, dosage form, route of administration, or an indication that has never been approved for the reference product.

That creates some interesting strategic opportunities. A biosimilar may, for example, move from a vial presentation to a prefilled syringe or auto-injector if the sponsor can support the change with appropriate performance, stability, extractables and leachables, and human factors data. At the same time, converting a lyophilized “for injection” product into a ready-to-use “injection” crosses the statutory line because FDA considers those different dosage forms.

The episode also explores a less obvious area: pediatric requirements. Non-interchangeable biosimilars can trigger PREA obligations because they are treated as having a new active ingredient for PREA purposes, but FDA does not interpret that to mean biosimilar sponsors must develop pediatric indications, strengths, or dosage forms that the reference product itself does not have. The 351(k) pathway effectively limits the scope of those pediatric obligations.

Postapproval manufacturing is another major theme. Once a biosimilar is licensed, manufacturers do not need to continue purchasing the reference product indefinitely every time they make a manufacturing change. FDA’s postapproval guidance allows routine comparability assessments to rely primarily on side-by-side evaluation of pre-change and post-change material, supported by a well-qualified in-house reference standard and ICH Q5E principles.

That is a meaningful lifecycle advantage. Changes such as scale-up, facility transfers, purification modifications, or new presentations can be managed through the appropriate PAS, CBE, or Annual Report pathway based on risk. In some cases, sponsors can also leverage the comparative analytical assessment generated during the original 351(k) application rather than repeating a complete head-to-head exercise against new reference product lots.

The broader takeaway is that FDA’s biosimilar framework has matured significantly. The pathway is not built around simply copying the innovator product forever. It is increasingly a lifecycle framework that gives sponsors meaningful flexibility while preserving strict boundaries around biosimilarity, product design, manufacturing comparability, and patient safety.

FDA Sources:Questions and Answers on Biosimilar Development and the BPCI Act, Revision 4: https://www.fda.gov/media/119258/download

Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Q&As: https://www.fda.gov/media/180206/download

Disclosure:Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.